Form 4: Bio-Rad EVP Evran Reports RSU Vesting, Stock Transactions

Bio-Rad Laboratories' EVP of Global Supply Chain, Sedat Evran, reported the vesting of restricted stock units and related stock transactions.

Summary

• Sedat Evran, Executive Vice President of Global Supply Chain at Bio-Rad Laboratories, Inc., reported transactions involving Class A Common Stock and Restricted Stock Units (RSUs).
• On September 5, 2025, Evran was granted 4,110 Restricted Stock Units (RSUs).
• On September 6, 2025, 864 RSUs vested, converting into 864 shares of Bio-Rad Class A Common Stock.
• Concurrently, 277 shares of Class A Common Stock were disposed of at a price of $295.43 per share to cover tax obligations related to the RSU vesting.
• Following these transactions, Evran beneficially owns 1,523.847 shares of Bio-Rad Class A Common Stock.
• Evran also holds 2,592 Restricted Stock Units.
• The reported Class A Common Stock holdings include shares acquired through the Bio-Rad Employee Stock Purchase Plan: 56.9880 shares on March 31, 2025, and 26.7190 shares on June 30, 2025.

Sentiment

Score: 7

Explanation: The filing reports routine executive compensation activities, including a new RSU grant and vesting of existing units, which are generally positive for executive alignment. The sale of shares for tax purposes is a neutral, standard event.

Positives

• Grant of 4,110 Restricted Stock Units (RSUs) to a key executive, aligning management incentives with shareholder interests.
• Vesting of 864 RSUs demonstrates the executive's continued equity accumulation.
• Participation in the Employee Stock Purchase Plan (ESPP) indicates ongoing executive investment in the company.

Negatives

• Disposition of 277 shares of Class A Common Stock to cover tax liabilities, which is a common practice but reduces direct shareholding.

Future Outlook

Restricted Stock Units granted on September 5, 2025, will vest over four years at 25% per year on the yearly anniversary date of the grant.

Industry Context

This Form 4 filing is a routine disclosure of executive stock transactions, common across all publicly traded companies. It reflects standard executive compensation practices involving equity grants and vesting schedules, which are prevalent in the life sciences and diagnostics industry where Bio-Rad operates.

Comparison to Industry Standards

• The RSU vesting and subsequent sale for tax purposes are standard practices for executive compensation in the U.S. public market.
• The vesting schedule of 25% per year over four years is a common structure designed to retain executives and align their long-term interests with shareholders.
• Companies like Thermo Fisher Scientific (TMO) and Danaher Corporation (DHR), also in the life sciences tools sector, utilize similar equity compensation structures for their executives.

Stakeholder Impact

• Shareholders: Executive equity ownership aligns management interests with shareholder value creation. The new RSU grant incentivizes long-term performance.
• Employees: The Employee Stock Purchase Plan (ESPP) mentioned indicates a broader program for employee equity participation.

Next Steps

• Continued vesting of the 4,110 Restricted Stock Units over the next four years, with 25% vesting annually on the grant anniversary date.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation and stock transactions, which are not typically considered material events that would significantly alter an investment thesis. The transactions reflect standard practices and do not provide new information warranting a change in investment recommendation based solely on this filing.

Keywords

Bio-Rad Laboratories, BIO, Sedat Evran, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Executive Compensation, Stock Transactions, Employee Stock Purchase Plan